Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10289399 | 0.85 | PIK3CD (0.48) | PIK3CDKCNA5RAB9A | |
| SCHEMBL5535641 | 0.79 | PIK3CD (0.40) | PIK3CDKCNA5RAB9A | |
| SCHEMBL4733460 | 0.78 | PIK3CD (0.43) | PIK3CDKCNA5RAB9A | |
| SCHEMBL19909618 | 0.76 | PIK3CD (0.58) | PIK3CDKCNA5RAB9A | |
| SCHEMBL12703399 | 0.76 | KCNA5 (0.43) | PIK3CDKCNA5RAB9A | |
| SCHEMBL25840124 | 0.74 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL24578095 | 0.74 | PIK3CD (0.40) | PIK3CDKCNA5RAB9A | |
| SCHEMBL5535647 | 0.74 | PIK3CD (0.40) | PIK3CDKCNA5RAB9A | |
| SCHEMBL13995359 | 0.74 | PIK3CD (0.50) | PIK3CDKCNA5RAB9A | |
| SCHEMBL18924283 | 0.73 | PIK3CD (0.39) | PIK3CDKCNA5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10913764-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PIK3CD 4518/4885KCNA5 880/4885RAB9A 915/4885 |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | PIK3CD 2074/4885KCNA5 3454/4885RAB9A 1019/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | PIK3CD 2012/4885KCNA5 4250/4885RAB9A 2937/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | PIK3CD 4518/4885KCNA5 880/4885RAB9A 915/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | PIK3CD 3160/4885KCNA5 4853/4885RAB9A 2446/4885 |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PIK3CD 2074/4885KCNA5 3454/4885RAB9A 1019/4885 |
| US-10913764-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | PIK3CD 3408/4885KCNA5 3720/4885RAB9A 3544/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | PIK3CD 158/4885KCNA5 2641/4885RAB9A 715/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | PIK3CD 3160/4885KCNA5 4853/4885RAB9A 2446/4885 |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PIK3CD 2074/4885KCNA5 3454/4885RAB9A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.